Apter joins as CEO to support the next stage of growth for the 
life-science reagents platform 
 
 
BOSTON--(BUSINESS WIRE)--August 28, 2025-- 
 
   Battery Ventures, a global, technology-focused investment firm, 
announced the completion of its take-private of Enzo Biochem ("Enzo"), a 
life-science research reagents company. 
 
 
   This press release features multimedia. View the full release here: 
https://www.businesswire.com/news/home/20250828987506/en/ 
 
 
   Enzo offers over 200,000 research reagents, including labeling and 
detection kits, antibodies, assays, and proteins for academic, 
pharmaceutical, and biotech research. Enzo's products are cited in more 
than 175,000 published studies across genomic, protein, cellular, and 
tissue analysis. 
 
 
   With its decades of expertise, Enzo has earned the trust of scientists 
worldwide for its deep catalog of products, commitment to quality and 
strong industry reputation. Battery's investment is intended to 
accelerate Enzo's next phase of innovation and growth by combining the 
company's strong brand and deep scientific expertise with Battery's 
track record of investing in life-science and research-tools companies 
globally. 
 
 
   "This investment comes after years of tracking Enzo, whom we consider a 
leader in the research-reagents market," said Justin Rosner, a Battery 
Ventures partner. "We're excited to build on Enzo's strong fundamentals 
and brand by helping the company develop new products, expand market 
share and pursue strategic acquisitions. Together, we'll prioritize 
operational excellence and strive to deliver value to Enzo's customers." 
 
 
   "We believe deeply in Enzo's growth potential and see Enzo as a 
foundation on which to build a world-class reagents business," said 
Jesse Feldman, a Battery Ventures general partner. Specifically, Battery 
will drive growth and innovation by supporting Enzo's core product and 
technical strengths; investing further in R&D; and pursuing targeted 
acquisitions to broaden the company's reach into new scientific research 
applications, as well as new global markets. 
 
 
   As part of this initiative, veteran life-science executive Jason Apter 
has joined Enzo as group CEO. Apter previously served as CEO of Sannova 
Analytical, an organization offering bioanalytical and analytical 
testing services to pharmaceutical and biotech companies. He also held 
senior leadership roles at MilliporeSigma and Johnson Matthey. 
 
 
   Apter will be supported on Enzo's board of directors by Battery's Rosner, 
Feldman and Alan Hirzel, the former CEO of biological-reagents company 
Abcam. 
 
 
   "I'm genuinely excited to collaborate with the board and the Enzo team 
as we move into a pivotal phase of the company's development," said 
Apter. "I look forward to applying my industry experience to accelerate 
growth, strengthen operational excellence and foster innovation, all 
under the banner of a highly respected brand." 
 
 
   About Enzo Biochem 
 
 
   For over 45 years, Enzo has provided enabling life science technologies 
for research, drug discovery, drug development, and diagnostic 
solutions. We are pioneers in labeling and detection, driven by our 
commitment to serving our customers, and enabling their pursuit of 
innovation. Our customer-focused approach, along with our teams of 
highly specialized expert scientists, enables us to be true scientific 
partners. Our technological expertise enables our customers to achieve 
their next great discoveries. Leveraging over 500 patents, our 
rigorously validated products with 175,000+ citations, world-class R&D 
and in-house manufacturing, we fuel the advancements that lead the way 
to a healthier world. 
 
 
   About Battery Ventures 
 
 
   Battery partners with exceptional founders and management teams 
developing category-defining businesses in markets including software 
and services, enterprise infrastructure, consumer tech, healthcare IT 
and industrial technology and life-science tools. Founded in 1983, the 
firm backs companies at all stages, ranging from seed and early to 
growth and buyout, and invests globally from offices in Boston, San 
Francisco, Menlo Park, New York, London, and Tel Aviv. Follow the firm 
on X @BatteryVentures, visit our website at www.battery.com and find a 
full list of Battery's portfolio companies here. 
 
 
 

View source version on businesswire.com: https://www.businesswire.com/news/home/20250828987506/en/

 
 
    CONTACT:    Rebecca Buckman 
 
   Marketing Partner 
 
   becky@battery.com 
 
 
   (650) 292-2077 
 
 
 
 
 
 

(END) Dow Jones Newswires

August 28, 2025 09:05 ET (13:05 GMT)